THE FUTURE OF DIAGNOSTICS
Accurate, rapid, and digital pathogen detection in bodily fluids to indicate in real-time which drugs will be most effective.
OUTLOOK
The U.S market for infectious disease diagnostics exceeds $20 billion annually, providing a significant opportunity for companies that provide more rapid and accurate solutions. Avails technology will serve the existing market by improving existing workflow and time-to-results. Providing physicians with AST results early on to inform their therapeutic decisions is critical to improving health outcomes.
SOLUTION
Avails is developing intuitive, streamlined, standalone applications, all based on its proprietary electrical biosensor platform. Applications will include electrical pathogen quantification, antibiotic susceptibility testing (AST) and identification of certain forms of resistance expressed in bacteria and fungi. Complimentary to direct rapid organism identification (ID), Avails platform will advance the in-vitro diagnostics market by enabling timely diagnostics-guided therapy, meaningfully reducing the time to most effective and targeted treatment. For the majority of infectious disease diagnoses, Avails is expected to reduce treatment decisions from days to several hours.
THERE ARE MANY MARKETS IN NEED FOR RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING (AST)
Urinary Tract Infection
Sepsis
Sexually Transmitted Diseases
MRSA
Meningitis
Pharyngitis
Dx-Guided Therapy
Avails Medical is being developed to allow diagnostic-guided therapy
Avails Technology
Time Savings
The platform is being developed to provide actionable results in hours instead of days
A big problem in a big market.
Avails Medical aims to become the world leader in accelerated antibiotic susceptibility testing, starting with the Sepsis (Bacteremia) diagnostics market. Sepsis costs the US healthcare system $24B+ annually, with more than 2 million new cases a year in the US alone. Between 40%-60% of infected people die – far more than the number of U.S. deaths from prostate cancer, breast cancer and AIDS combined.
